Neuroscience
In Preventing Alzheimer’s, Mutation May Aid Drug Quest
The New York Times
By GINA KOLATA
11 July 2012
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
A fuller report from The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By GINA KOLATA The New York Times Published: January 20, 2011 "A committee voted that the agency should approve the first test that can show the characteristic...
- Alzheimer's Disease: A-beta And Immune System
Old Enemy Might Help to Prevent Alzheimer’s By GINA KOLATA The New York Times Published: March 8, 2010 "Harvard researchers are taking a new look at beta amyloid, which was thought to be a chief villain in Alzheimer’s whose function was that of a...
- Neuropsychology Abstract Of The Day: Alzheimer Drug Development
Today's recommended article to read; abstract from PubMed: Bergmans BA & De Strooper B. gamma-secretases: From cell biology to therapeutic strategies. Lancet Neurology. 2010 Feb; 9(2 ): 215-226. Department of Molecular and Developmental Genetics,...
- Alzheimer Disease
From The Boston Globe: Mind mystery Alzheimer's disease appears to have multiple causes, and scientists are slowly unraveling them By Alice Dembner, Globe Staff March 29, 2005 A century after Alois Alzheimer identified the debilitating dementia that...
Neuroscience
Alzheimer's Disease
In Preventing Alzheimer’s, Mutation May Aid Drug Quest
The New York Times
By GINA KOLATA
11 July 2012
[snip]
Two decades ago, researchers began discovering rare gene mutations that cause Alzheimer’s disease in all who inherit them. Now, they have found the opposite: a mutation that prevents the devastating brain disorder. The protective mutation also is very rare — it is not the reason most people do not develop Alzheimer’s disease. But what intrigues researchers is how it protects the brain. It does the reverse of what the mutations that cause Alzheimer’s do. Those mutations lead to excessive amounts of a normal substance, beta amyloid, in the brain. The protective mutation slows beta amyloid production, so people make much less.
[snip]
Read the full article
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
A fuller report from The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By GINA KOLATA The New York Times Published: January 20, 2011 "A committee voted that the agency should approve the first test that can show the characteristic...
- Alzheimer's Disease: A-beta And Immune System
Old Enemy Might Help to Prevent Alzheimer’s By GINA KOLATA The New York Times Published: March 8, 2010 "Harvard researchers are taking a new look at beta amyloid, which was thought to be a chief villain in Alzheimer’s whose function was that of a...
- Neuropsychology Abstract Of The Day: Alzheimer Drug Development
Today's recommended article to read; abstract from PubMed: Bergmans BA & De Strooper B. gamma-secretases: From cell biology to therapeutic strategies. Lancet Neurology. 2010 Feb; 9(2 ): 215-226. Department of Molecular and Developmental Genetics,...
- Alzheimer Disease
From The Boston Globe: Mind mystery Alzheimer's disease appears to have multiple causes, and scientists are slowly unraveling them By Alice Dembner, Globe Staff March 29, 2005 A century after Alois Alzheimer identified the debilitating dementia that...